Sandeep Walia, MD
Ophthalmology · Bakersfield, CANPI 1750791661
Payments from drug & device makers
Across 340 payments — averaging $237.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$39K
- Rxsight Inc$25K
- Amneal Pharmaceuticals LLC$7K
- Carl Zeiss Meditec USA, Inc.$3K
- Alcon$1K
- Amgen$1K
- plus $4K from 20 others
Across 1 payment — averaging $3500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$4K
What the payments were for
- Consulting fees$2,8756%
- Speaking & faculty fees$33,01364%
- Travel & lodging$7,46915%
- Food & beverage$7,89315%
- Education$560%
- Entertainment$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 55 | $39,392 |
| Rxsight Inc | 21 | $25,129 |
| Amneal Pharmaceuticals LLC | 7 | $7,285 |
| Carl Zeiss Meditec USA, Inc. | 7 | $2,825 |
| Alcon | 53 | $1,438 |
| Amgen(2 entities) | 41 | $1,071 |
| Glaukos Corporation | 13 | $746 |
| AbbVie(2 entities) | 35 | $659 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $316 |
| Sun Pharmaceutical Industries Inc. | 15 | $298 |
| Aerie Pharmaceuticals, Inc. | 23 | $293 |
| Novartis | 15 | $271 |
| Dompe US, Inc. | 5 | $211 |
| Sight Sciences, Inc. | 8 | $183 |
| Kala Pharmaceuticals, Inc. | 7 | $156 |
| Harrow Eye, LLC | 2 | $58 |
| Tarsus Pharmaceuticals, Inc. | 3 | $55 |
| Optos, Inc. | 2 | $54 |
| Oyster Point Pharma, Inc. | 2 | $50 |
| Biotissue Holdings Inc. | 2 | $34 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Omeros Corporation | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Thea Pharma Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$21,911
- XIIDRA$12,425
- LOTEMAX SM$5,175
- RXSIGHT CONTACT LENS$2,999
- RXSIGHT INJECTOR CARTRIDGE$2,999
- RXSIGHT INJECTOR HANDPIECE$2,999
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$2,999
- LIGHT ADJUSTABLE LENS (LAL)$2,999
- ARTEVO 800$2,667
- CIRRUS HD-OCT$2,554
- IOLMaster 700$2,554
- VisuMax$2,554
- QUATERA 700$2,554
- TEPEZZA$528
- NGENUITY$386
- Rhopressa$225
- Rocklatan$225
- SURGICAL MISC$141
- iStent Trabecular Micro-Bypass Stent System$139
- iStent inject Trabecular Micro-Bypass Stent System$139
How this compares
$80,645 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 173 | $84,179 |
| RestasisCyclosporine | 43 | $40,823 |
| MieboPerfluorohexyloctane/Pf | 28 | $27,975 |
| Alphagan PBrimonidine Tartrate | 80 | $25,883 |
| XiidraLifitegrast | 14 | $17,311 |
| CombiganBrimonidine Tartrate/Timolol | 46 | $15,916 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $14,870 |
| Latanoprost | 1,188 | $11,419 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 46 | $11,024 |
| Brimonidine Tartrate | 115 | $10,214 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 484 | $8,113 |
| VyzultaLatanoprostene Bunod | 12 | $8,112 |
| RhopressaNetarsudil Mesylate | 13 | $7,254 |
| Prednisolone Acetate | 212 | $6,089 |
| Brinzolamide | 22 | $4,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $659 | $166,801342 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra, Vyzulta | $39,392 | $53,39854 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $293 | $22,12446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Bakersfield
- Daniel ChangBakersfield$3.5M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.